The University of North Carolina at Charlotte received a three-year Project Grant totaling $900,538 from the National Cancer Institute within the Department of Health and Human Services. The grant falls under the Cancer Detection and Diagnosis Research program (CFDA 93.394), which aims to improve cancer screening, early detection, and diagnostic techniques.
The university will develop a multimodal nanoparticle platform for the efficient treatment of triple-negative breast cancer. Researchers will design, synthesize, and characterize two silica-based nanoparticle systems carrying the photosensitizing agent chlorin e6 and novel RNA fiber therapeutics targeting the anti-apoptotic protein BCL2. In vitro studies will evaluate the therapeutic and gene silencing effects, impact on cell death mechanisms, and immune response. Based on these results, the best-performing platform will be selected for investigation of therapeutic efficacy and effects on metastasis in an orthotopic triple-negative breast cancer model. The goal is to provide an alternative treatment approach with potential immunological benefits for this aggressive cancer subtype.
Generated 1/6/24, 8:09 PM